Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Richard B Lipton, Robert Croop, Elyse G Stock...
https://pubmed.ncbi.nlm.nih.gov/31291516/Actively Recruiting
Led by University of Florence · Updated on 2026-06-11
100
Participants Needed
2
Research Sites
34 weeks
Total Duration
This research aims to evaluate how well rimegepant works and how well patients tolerate it when used as a preventive treatment for people with episodic or chronic migraine. Rimegepant is a new type of small molecule that blocks the calcitonin gene-related peptide CGRP receptor, available as a 75 mg orally disintegrating tablet. Previous trials showed its potential in preventing migraines and its tolerability, with common side effects like nausea and infections. Participants will take rimegepant 75 mg every other day for up to two years, depending on reimbursement approval. This study is prospective and multicentric, enrolling patients who meet specific criteria and collecting baseline demographic and clinical information. Data are gathered at baseline and every three months during the two-year observation period. During the study, participants will keep a headache diary recording monthly headache and migraine days, migraine severity, related symptoms, and medication use. Researchers will collect questionnaires and monitor demographic data, migraine history, pain intensity, associated symptoms, disability, side effects, treatment persistence, and quality of life through an online database. The main outcomes include changes in migraine frequency and the percentage of patients with at least a 50% reduction in monthly migraine days after three months of treatment.
CONDITIONS
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
L
Luigi F Iannone, MD
R
Roberto De Icco, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Florence
Lead Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants take rimegepant 75 mg orally disintegrating tablet every other day as preventive treatment for migraine.
Visits every 3 months for assessments and questionnaires
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Richard B Lipton, Robert Croop, Elyse G Stock...
https://pubmed.ncbi.nlm.nih.gov/31291516/Robert Croop, Richard B Lipton, David Kudrow...
https://pubmed.ncbi.nlm.nih.gov/33338437/University of Florence
Lead Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborating Sponsor